Newer antiepileptic drugs in the treatment of status epilepticus: impact on prognosis

Fiche du document

Auteur
Date

2011

Type de document
Périmètre
Langue
Identifiant
Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_2A5B6F8B80C15

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer



Sujets proches En

Use of

Citer ce document

L. Jaques, « Newer antiepileptic drugs in the treatment of status epilepticus: impact on prognosis », Serveur académique Lausannois, ID : 10670/1.kgqamz


Métriques


Partage / Export

Résumé 0

Background: Newer antiepileptic drugs (AED) are increasingly prescribed, and seem to have a comparable efficacy as the classical AED, but are better tolerated. Very scarce data exist regarding their prognostic impact in patients with status epilepticus (SE). We therefore analyzed the evolution of prescription of newer AED between 2006-2010 in our prospective SE database, and assessed their impact on SE prognosis.¦Methods: We found 327 SE episodes occurring in 271 adults. The use of older versus newer AED (levetiracetam, pregabalin, topiramate, lacosamide) and its relationship to outcome (return to clinical baseline conditions, new handicap, or death) were analyzed. Logistic regression models were applied to adjust for known SE outcome predictors.¦Results: We observed an increasing prescription of newer AED over time (30% of patients received them at the study beginning, vs. 42% towards the end). In univariate analyses, patients treated with newer AED had worse outcome than those treated with classical AED only (19% vs 9% for mortality; 33% vs 64% for return to baseline, p

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en